Supplementary Table 1. Comparison of patients who answered the questionnaire on their experience during transition to the adult service and those who did not answer the questionnaire

	Patients who answered the questionnaire $(N=35)$	Patients who did  not answer the  questionnaire  (N = 17)	P value
Age (years) at transition, mean $\pm$ SD	$18.4 \pm 0.8$	$18.6 \pm 1.1$	0.75
Sex (female), n (%)	20 (57%)	6 (35.3%)	0.24
BMI (kg/m <sup>2</sup> ), mean $\pm$ SD	$24.3 \pm 6.2$	$24.2\pm4.2$	0.63
Age of asthma onset (years), mean $\pm$ SD	$4.1\pm3.9$	$3.4 \pm 3.8$	0.6
Asthma phenotype, n (%)			
Allergic asthma (eosinophilic)	26 (74.3%)	12 (70.6%)	1
Asthma and allergic poly-morbidities	21 (60%)	12 (70.6%)	0.55
Non-allergic eosinophilic asthma	3 (8.6%)	2 (11.8%)	1
Non-allergic non-eosinophilic asthma	6 (1.7%)	3 (17.6%)	1
Asthma and poly-morbidities	8 (2.3%)	2 (11.8%)	0.47
Asthma treatment at transition, n (%)			
ISC: dose equivalent of budesonide			
Mean/median	1216 / 1000	1659/2000	0.43
Low dose	4 (11.4%)	3 (17.6%)	0.67
Moderate dose	6 (17.1%)	4 (23.5%)	0.71
High dose	25 (71.4%)	10 (58.8%)	0.53
Biologics, n (%)	12 (34.3%)	7 (41.2%)	0.76
Omalizumab	11 (31.4%)	6 (35.3%)	
Mepolizumab	0 (0%)	1 (5.9%)	
Benralizumab	0 (0%)	0 (0%)	

Dupilumab	1 (2.9%)	0 (0%)	
Adherence to treatment, n (%)			
Good	25 (71.4%)	11 (64.7%)	0.75
Moderate	9 (25.7%)	6 (35.3%)	0.52
Poor	1 (2.9%)	0 (0%)	1
Smoking active, n (%)	3 (8.6%)	0 (0%)	0.54
ACT score (mean/median/SD)			
Baseline	21.6 / 23 / 3.6	17.4 / 19 / 6.5	0.72
6 months	21.1 / 22 / 4.5	18.5 / 19 / 5.4	0.14
12 months	20.5 / 23 / 4.9	19.9 / 22 / 5.3	0.80
24 months	20.1 / 21 / 4.4	20.7 / 23 / 5.3	0.53
36 months	19.9 / 20 / 5	20 / 20 / 4.7	0.94
Patients with no regular follow-up for			
>12 months in the adult centre, n (%)	11 (31.4%)	8 (47%)	0.36
Mean duration between 2 consultations	23	24.6	0.97
(months)			

**Notes**: Data are shown as the mean  $\pm$  standard deviation (SD), median or number (%). P-values were obtained using the Fisher's exact test or the Wilcoxon-Mann Whitney test, as appropriate. A p-value of < 0.05 was considered statistically significant.

Abbreviations: BMI, body mass index; ICS, inhaled corticosteroid; ACT, asthma control test